RMTI — Rockwell Medical Income Statement
0.000.00%
Last trade - 00:00- $39.98m
- $28.65m
- $101.49m
- 71
- 82
- 54
- 79
Annual income statement for Rockwell Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 62.2 | 61.9 | 72.8 | 83.6 | 101 |
| Cost of Revenue | |||||
| Gross Profit | 2.73 | -2.42 | 4.08 | 8.7 | 17.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 90.6 | 92.3 | 89.6 | 90.3 | 101 |
| Operating Profit | -28.4 | -30.3 | -16.8 | -6.67 | 0.608 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -30.9 | -32.7 | -18.7 | -8.44 | -0.48 |
| Net Income After Taxes | -30.9 | -32.7 | -18.7 | -8.44 | -0.48 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -30.9 | -32.7 | -18.7 | -8.44 | -0.48 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -30.9 | -32.7 | -18.7 | -8.44 | -0.48 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.49 | -3.83 | -1.89 | -0.362 | -0.015 |